



Príomhoifigeach Cliniciúil
Oifig an Phríomhoifigigh Cliniciúil

Ospidéal Dr Steevens, Lána Steevens
Baile Átha Cliath 8 , D08 W2A8

Chief Clinical Officer
Office of the Chief Clinical Officer

Dr Steevens Hospital, Steevens Lane
Dublin 8, D08 W2A8

www.hse.ie
[@hselive](https://twitter.com/hselive)

t 01 635 2000
e cco@hse.ie

BY EMAIL ONLY

Deputy Róisín Shortall
Dáil Éireann
Leinster House
Kildare Street
Dublin 2

14th March 2022

PQ 12687/22 Deputy Róisín Shortall - To ask the Minister for Health if the Therapeutics Advisory Group is reviewing a product (details supplied); if he expects this monoclonal antibody treatment to be added to the agreed list of novel therapeutics; the stocks that have been purchased; and if he will make a statement on the matter.

Dear Deputy Shortall,

Thank you for your representation.

The Therapeutics Advisory Group is planning to review the product Evusheld. The Department of Health and the HSE's Chief Clinical Officer are working to coordinate a meeting with AstraZeneca and the Therapeutics Advisory Group to discuss the matter further. It is anticipated that this meeting will take place this week.

In addition to this, the CCO has requested a rapid evidence synthesis review on Evusheld from the National Centre for Pharmacoeconomics.

Pending all of this investigative work a decision will be made as to whether this treatment will be added to the agreed list of novel therapeutics. After this, stocks of Evusheld may be considered for purchase.

I hope this provides you with assistance.

Yours sincerely

Sharon Hayden
General Manager
Office of the CCO